STTCOMP MEB, FA Long
MC: $43 mill
Price: $0.28
Medibio Limited (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio’s depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio’s application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio’s technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market.
Data collection for the exploratory (n=60) study is largely complete, with most of the data having been reviewed for quality and preliminarily analysed. MEB will use the results from this study, in consultation with FDA, to inform the final sample size of the confirmatory study. Results are due in the current quarter.
- Forums
- ASX - Short Term Trading
- Short Term Trading Week Starting: - 22 May
STTCOMP MEB, FA Long MC: $43 mill Price: $0.28 Medibio Limited...
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)